Joshua Hare
Known title: Chief Scientific OfficerCIK: 0001449392
Joshua Hare's purchase track record
Joshua Hare has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/10/2024 | LGVN | $350K | +102.2% | -18.2% | +12.2% |
| 10/7/2021 | LGVN | $26K | +198.5% | +214.3% | +2.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LGVN | ▲ Buy | Grant | 286,000 | $0 | 8/19/2026 | View on chart |
| LGVN | ▲ Buy | Grant | 600,000 | $0 | 7/6/2026 | View on chart |
| LGVN | ▼ Sell | Open Market | 5,250 | $7K | 5/16/2025 | View on chart |
| LGVN | ▲ Buy | Grant | 93,766 | $0 | 8/15/2024 | View on chart |
| LGVN | ▲ Buy | Open Market | 42,553 | $100K | 4/11/2024 | View on chart |
| LGVN | ▲ Buy | Open Market | 106,383 | $250K | 4/10/2024 | View on chart |
| LGVN | ▲ Buy | Option Exercise | 5,000 | $15K | 9/21/2023 | View on chart |
| LGVN | ▲ Buy | Option Exercise | 30,000 | $90K | 9/12/2023 | View on chart |
| LGVN | ▼ Sell | Open Market | 20,000 | $86K | 1/27/2023 | View on chart |
| LGVN | ▼ Sell | Open Market | 20,000 | $75K | 12/2/2022 | View on chart |
| LGVN | ▲ Buy | Grant | 48,140 | $0 | 11/16/2022 | View on chart |
| LGVN | ▼ Sell | Open Market | 100,000 | $361K | 10/12/2022 | View on chart |
| LGVN | ▼ Sell | Open Market | 78 | $780 | 4/19/2022 | View on chart |
| LGVN | ▼ Sell | Open Market | 19,922 | $199K | 4/18/2022 | View on chart |
| LGVN | ▲ Buy | Open Market | 2,500 | $9K | 10/12/2021 | View on chart |
| LGVN | ▲ Buy | Open Market | 3,015 | $10K | 10/8/2021 | View on chart |
| LGVN | ▲ Buy | Open Market | 1,985 | $7K | 10/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Longeveron to speak at three longevity investment conferences
Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.
Longeveron to speak at three longevity investment conferences. Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.